Transient receptor potential Vanilloid 1-based gene therapy alleviates orthodontic pain in rats.
10.1038/s41368-019-0044-3
- Author:
Rui GUO
1
;
Yang ZHOU
1
;
Hu LONG
2
;
Di SHAN
3
;
Jing WEN
1
;
Huimin HU
1
;
Hong YANG
1
;
Zhouqiang WU
1
;
Wenli LAI
4
Author Information
1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
2. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China. hlong@scu.edu.cn.
3. Jiangsu Key Laboratory of Oral Diseases, Department of Orthodontics, Stomatology Hospital Affiliated with Nanjing Medical University, Nanjing, China.
4. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China. wenlilai@scu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
Calcitonin Gene-Related Peptide;
Genetic Therapy;
Male;
Molar;
Pain;
Quality of Life;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
TRPV Cation Channels;
Tooth Movement Techniques;
Trigeminal Ganglion
- From:
International Journal of Oral Science
2019;11(1):11-11
- CountryChina
- Language:English
-
Abstract:
Orthodontic pain that is induced by tooth movement is an important sequela of orthodontic treatment and has a significant effect on patient quality of life. Studies have shown that the high expression of transient receptor potential vanilloid 1 (TRPV1) in trigeminal ganglions plays a vital role in the transmission and modulation of orofacial pain. However, little is known about the role of TRPV1 in orthodontic pain. In this study, male Sprague-Dawley rats were randomly assigned to six groups to study the role of TRPV1 in the modulation of tooth-movement pain. The expression levels of TRPV1 mRNA and protein were determined by real-time PCR and western blot, respectively. Moreover, pain levels were assessed using the rat grimace scale (RGS). The role of TRPV1 in modulating tooth-movement pain was examined by injecting a TRPV1 antagonist into the trigeminal ganglia of rats. A lentivirus containing a TRPV1 shRNA sequence was constructed and transduced into the rats' trigeminal ganglia. The results showed that the expression levels of TRPV1 protein and mRNA were elevated following tooth-movement pain. Pain levels increased rapidly on the 1 day, peaked on the 3 day and returned to baseline on the 14 day. The TRPV1 antagonist significantly reduced tooth-movement pain. The lentivirus containing a TRPV1 shRNA sequence was able to inhibit the expression of TRPV1 and relieved tooth-movement pain. In conclusion, TRPV1-based gene therapy may be a treatment strategy for the relief of orthodontic pain.
